Compare Merck & Co., Inc. (MRK) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Novavax Inc — how do they compare? Merck & Co., Inc. trades at $147.7 (market cap $363.98B), while Novavax Inc trades at $9.8 (market cap $1.62B). The key difference: Merck & Co., Inc. is far larger — about 224.7× Novavax Inc's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MRK | NVAX | |
|---|---|---|
Market Cap | $363.98B | $1.62B |
Sector | Health | Health |
52-Week High | $156.43 | $11.19 |
52-Week Low | $77.60 | $6.22 |
Enterprise Value | $410.75B | $1.20B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with $65.01B revenue and $18.25B net income, though Q1 and Q2 2026 show losses. Recent acquisition of Terns Pharmaceuticals for $6.7B aims to bolster its oncology pipeline. Analyst consensus is strongly bullish with 67.6% buy ratings and a $157 price target, representing 5.7% upside.
Merck presents a compelling investment case with solid fundamentals and strategic acquisitions, but faces risks from patent expirations and competitive pressures. The stock offers moderate upside potential with institutional support, though investors should monitor execution of growth initiatives and pipeline developments in the competitive pharmaceutical landscape.
Novavax (NVAX) trades at $10.19, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, but faces negative cash flow trends. Recent news highlights regulatory approvals for its COVID-19 vaccine and partnership milestones with Sanofi, driving investor optimism despite ongoing financial challenges.
The outlook for NVAX is mixed; analyst consensus is 74% buy with potential from vaccine approvals and partnerships, but risks include persistent negative cash flows, high debt, and competitive pressures. Investors should weigh the promising pipeline against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
